Sands Capital Management
MRTX

Sands Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sands Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-393,886
Closed -$86.5M – 78
2020
Q4 		$86.5M Sell
393,886
-936,816
-70% -$203M 0.16% 60
2020
Q3 		$221M Sell
1,330,702
-837,870
-39% -$115M 0.48% 48
2020
Q2 		$248M Sell
2,168,572
-79,437
-4% -$7.7M 0.6% 44
2020
Q1 		$173M Buy
2,248,009
+446,269
+25% +$40M 0.58% 42
2019
Q4 		$232M Buy
1,801,740
+470,757
+35% +$45.4M 0.67% 37
2019
Q3 		$104M Sell
1,330,983
-48,631
-4% -$4.56M 0.33% 48
2019
Q2 		$142M Buy
+1,379,614
New +$107M 0.42% 41

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management's MRTX Position: Q1 2021 in Review

Sands Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 393,886 shares — an estimated $86.5M sold.

Sands Capital Management first reported a position in MRTX in Q2 2019 and held it in 7 quarters. The position peaked at $248M in Q2 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • Sands Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Sands Capital Management sold 393,886 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $86.5M.
  • Sands Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 7 quarters.
  • Sands Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $248M in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Sands Capital Management's 13F filing for Q1 2021, filed 12 May 2021.